Literature DB >> 9287972

The C-X-C chemokine ENA-78 is preferentially expressed in intestinal epithelium in inflammatory bowel disease.

K Z'Graggen1, A Walz, L Mazzucchelli, R M Strieter, C Mueller.   

Abstract

BACKGROUND & AIMS: Secretion of chemokines by epithelial cells may represent a crucial event in the pathogenesis of inflammatory bowel disease (IBD). Expression of the chemokine epithelial neutrophil-activating peptide 78 (ENA-78) was monitored in patients with IBD and normal controls.
METHODS: In situ hybridizations were performed on 41 tissue specimens from 15 patients with IBD and 10 controls to detect ENA-78 messenger RNA (mRNA). Immunofluorescence stainings were used to localize ENA-78 protein.
RESULTS: Intestinal epithelial cells expressing ENA-78 mRNA at detectable levels are found at comparable frequencies in patients with Crohn's disease and ulcerative colitis. Tissue specimens with mild to moderate histological signs of disease activity show slightly higher frequencies of ENA-78 mRNA-expressing epithelial cells than areas with signs of severe disease activity (P = 0.14). Immunofluorescence stainings showed presence of the ENA-78 protein in > 90% of preserved epithelial cells in IBD, in control tissues, ENA-78 mRNA was not detectable, and ENA-78 protein was detectable in 0%-30% of epithelial cells.
CONCLUSIONS: The observations are in agreement with a role of the C-X-C chemokine ENA-78 in the pathogenesis of IBD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9287972     DOI: 10.1016/s0016-5085(97)70175-6

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  34 in total

1.  Increased expression of chemokine receptor CCR3 and its ligands in ulcerative colitis: the role of colonic epithelial cells in in vitro studies.

Authors:  P Manousou; G Kolios; V Valatas; I Drygiannakis; L Bourikas; K Pyrovolaki; I Koutroubakis; H A Papadaki; E Kouroumalis
Journal:  Clin Exp Immunol       Date:  2010-11       Impact factor: 4.330

Review 2.  Chemokines in inflammatory bowel disease.

Authors:  S Danese; A Gasbarrini
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

Review 3.  Layers of mutualism with commensal bacteria protect us from intestinal inflammation.

Authors:  C Mueller; A J Macpherson
Journal:  Gut       Date:  2006-02       Impact factor: 23.059

4.  Activated CD4+ and CD8+ cytotoxic cells are present in increased numbers in the intestinal mucosa from patients with active inflammatory bowel disease.

Authors:  S Müller; J Lory; N Corazza; G M Griffiths; K Z'graggen; L Mazzucchelli; A Kappeler; C Mueller
Journal:  Am J Pathol       Date:  1998-01       Impact factor: 4.307

5.  The effect of impaired angiogenesis on intestinal function following massive small bowel resection.

Authors:  Jose Diaz-Miron; Raphael Sun; Pamela Choi; Joshua Sommovilla; Jun Guo; Christopher R Erwin; Junjie Mei; G Scott Worthen; Brad W Warner
Journal:  J Pediatr Surg       Date:  2015-03-14       Impact factor: 2.545

6.  Intestinal inflammatory biomarkers and outcome in pediatric Clostridium difficile infections.

Authors:  Rana E El Feghaly; Jennifer L Stauber; Phillip I Tarr; David B Haslam
Journal:  J Pediatr       Date:  2013-09-04       Impact factor: 4.406

7.  Upregulation of Reg 1alpha and GW112 in the epithelium of inflamed colonic mucosa.

Authors:  S Shinozaki; T Nakamura; M Iimura; Y Kato; B Iizuka; M Kobayashi; N Hayashi
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

8.  Enhanced production of monocyte chemotactic protein 3 in inflammatory bowel disease mucosa.

Authors:  J Wedemeyer; A Lorentz; M Göke; P N Meier; P Flemming; C A Dahinden; M P Manns; S C Bischoff
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

9.  MIP-2 secreted by epithelial cells increases neutrophil and lymphocyte recruitment in the mouse intestine.

Authors:  Y Ohtsuka; J Lee; D S Stamm; I R Sanderson
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

10.  Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection.

Authors:  Rana E El Feghaly; Jennifer L Stauber; Elena Deych; Carlos Gonzalez; Phillip I Tarr; David B Haslam
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.